A5075022478- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Screening and Detection
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Urinary and Genital Oncology Studies
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Renal and related cancers
- Prostate Cancer Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Streptococcal Infections and Treatments
- Axon Guidance and Neuronal Signaling
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Hippo pathway signaling and YAP/TAZ
- Cardiac, Anesthesia and Surgical Outcomes
University of Southern California
2015-2025
USC Norris Comprehensive Cancer Center
2014-2023
Pasteur Institute of Iran
2018
Cleveland Clinic
2011-2015
Case Western Reserve University
2011-2015
Cleveland Clinic Lerner College of Medicine
2015
University Hospitals Cleveland Medical Center
2015
Southern California University for Professional Studies
2013
APLA Health
2012
Institut Gustave Roussy
2011
Colorectal cancer is the second leading cause of death in United States. Approximately 3% colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding optimal screening strategy for Using an individual level microsimulation a population affected by syndrome over several years, effectiveness and cost-effectiveness 21 strategies were compared. Modeling assumptions based upon published literature, sensitivity analyses performed key assumptions. In two-step process, number...
BACKGROUND Screening for colorectal cancer (CRC) has been successful in decreasing the incidence and mortality from CRC. Although new screening tests have become available, their relative impact on CRC outcomes remains unexplored. This study compares of various strategies outcomes. METHODS A Markov model representing natural history was built validated against empiric data trials as well Microstimulation Analysis (MISCAN) model. Thirteen based colonoscopy, sigmoidoscopy, computed tomographic...
TPS887 Background: UC is the 2nd most common genitourinary cancer. Enfortumab vedotin (EV) + pembrolizumab became a SOC in 2023 frontline mUC setting. There not established standard of care for subsequent lines therapy limiting treatment options to platinum-based chemotherapy, docetaxel, paclitaxel, gemcitabine, or Sacituzumab govitecan monotherapy. Erdafitinib remains an option pts with FGFR3 alterations. A phase I/II CTEP study eribulin (E) activity E objective response rate (ORR) 37.5%,...
PI3K pathway activation is a common and early event in prostate cancer, from loss of function mutations PTEN, or activating PIK3Ca AKT leading to constitutive activation, induction growth factor-receptors kinase EphB4 its ligand ephrin-B2. We hypothesized that an required for tumor initiation. Secondly, we remains relevant when cancer becomes androgen independent. Genetic mouse model conditional PTEN deletion epithelium induces all mice. tested this against EPHB4 wild type deleted...
Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed ligand 1 antibodies low response rates and thus there exists a major unmet need.In this phase II trial, patients that recurred or progressed platinum-based chemotherapy received soluble EphB4-human serum albumin (sEphB4-HSA) in combination pembrolizumab. The primary end points were tolerability overall survival (OS). secondary...
Abstract BACKGROUND: The current treatment of metastatic renal cell carcinoma (mRCC) with vascular endothelial growth factor (VEGF)‐targeted agents is continuous therapy until progression disease (PD) or unacceptable toxicity. Chronic mild to moderate toxicity and risk long‐term ensue for some patients. It hypothesized that patients an initial response can maintain control off all a period time. METHODS: A retrospective study mRCC who initiated VEGF‐targeted between January 2004 December...
The purpose of this study was to determine the factors which can help predict operative mortality before performing operation, and afterwards.The population consisted 504 patients (91 women 413 men) who underwent primary isolated coronary artery bypass surgery from December 1997 September 1999 by same surgeon in a referral center Tehran, Iran. Perioperative data were gathered analyzed both univariate multivariate model.After operation spent 7.3 +/- 4.0 days hospital. total morbidity 20.5%....
Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Therapy Evaluation Program-sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribulin combination in this population.
4529 Background: Immune checkpoint blockade has revolutionized mRCC Tx, but primary and acquired resistance continues to result in poor patient outcomes. OX40 (CD-134) mediates IO resistance. Co-stimulatory activates exhausted T-cells. activation dendritic cells increases the proliferation, effector function, survival of T cells. PFOX is an agonist for OX40. We hypothesized that + VEGFR inhibitor Axi would improve outcomes vs. patients (pts) with after Tx. Methods: Pts predominantly clear...
4531 Background: Modern therapy (Tx) for GCC has transformed the disease but challenges remain in managing rGCT. Methods: 30 men with progression ≤4 weeks after a standard (7), salvage (17), or stem cell (6) regimen were enrolled trial. PS<=2, Age>16, PD by RECIST/markers (Tm) criteria. Growing teratoma syndrome excluded. Regimen: paclitaxel 170mg/m 2 /3h; gemcitabine 800mg/m /80min; oxaliplatin 100mg/m /90min, increased to 125mg/m cycle if no major toxicity. Mg 2+ and Ca infused...
Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with fluoropyrimidines. Impact of oxaliplatin-containing regimens elderly stage II patients in real-world setting is unknown. We explored the utilization outcome AC after Food Drug Administration (FDA) approval oxaliplatin.Patients colon cancer (2004-2011) who underwent resection were selected this analysis. Medicare claims data used to...